Cocoon

The firm has developed a proprietary technological platform for the bioproduction of enzymes and other proteins. This platform utilizes insects, specifically the chrysalis of the Trichoplusia ni moth (cabbage looper), as single-use, natural bioreactors. This method is positioned as a more sustainable and cost-effective alternative to traditional fermentation-based production systems, which often require significant capital investment and have a larger environmental footprint. The automated process is designed to be highly scalable, enabling the production of high-performance growth factors and enzymes with greater speed and flexibility.

Cocoon Bioscience targets a diverse client base across multiple high-growth sectors, including the food technology industry for cultivated meat, the animal health market, and the assisted reproduction sector. By providing essential components like growth factors, which are crucial for cellular agriculture, the company addresses a key bottleneck in the production of lab-grown meat. The business model appears to be centered on business-to-business (B2B) sales of these high-value biological products manufactured through its unique insect-based platform.

A significant milestone in the company's early history was securing a €5 million seed funding round in January 2023, co-led by the Columbus Venture Partners’ SCR-Columbus Life Science Fund II and the venture capital firm Clave Capital. This investment was earmarked for scaling up production, expanding the team, and consolidating the company's presence in international markets. The company's technology is also recognized for its potential in producing reagents for diagnostics and Active Pharmaceutical Ingredients (APIs). Keywords: insect bioreactors, protein production, growth factors, cellular agriculture, cultivated meat, biomanufacturing, enzymes, animal health, food technology, biotechnology